aTYR PHARMA ATYR Institutional Ownership

Updated Oct 11, 2026

aTYR PHARMA INC (NASDAQ:ATYR) was reported as a holding by 91 institutional investors in 13F filings for the quarter ended June 30, 2026.

• Their combined stake equaled 39.80% of outstanding shares in Q2 2026, down from 57.76% in Q1 2026.
• Total shares held in aTYR PHARMA fell 31.06% versus Q1 2026, while the number of holders fell 14.95% versus Q2 2025.
• Of the 91 holders, 45 added to their positions, 31 reduced their stakes and 15 left their positions unchanged in Q2 2026.
• Combined, institutional investors held 39.04Mn shares of ATYR as of Q2 2026, down 17.59Mn from the prior quarter and down 26.94Mn from a year earlier.
• Federated Hermes, Inc. was the top holder of aTYR PHARMA as of June 30, 2026, with 8.51Mn shares, or 8.68% of shares outstanding.
• The biggest increases in ATYR positions during Q2 2026 came from AQR Capital Management LLC (+2.11Mn shares), GSA Capital Partners LLP (+1.77Mn shares), Jane Street Group, LLC (+1.67Mn shares), Citadel Advisors LLC (+1.19Mn shares) and Goldman Sachs Group Inc (+357.97K shares).
• The largest position reductions in ATYR for Q2 2026 were by FMR LLC (-12.24Mn shares), BlackRock, Inc. (-4.62Mn shares), UBS Group AG (-2.34Mn shares), Federated Hermes, Inc. (-2Mn shares) and State Street Corp (-1.26Mn shares).
• aTYR PHARMA's 10 largest institutional shareholders as of Q2 2026 were Federated Hermes, Inc. (8.51Mn shares), Vanguard Capital Management LLC (3.81Mn shares), GSA Capital Partners LLP (3.45Mn shares), AQR Capital Management LLC (2.61Mn shares), FMR LLC (2.47Mn shares), BlackRock, Inc. (1.83Mn shares), Kalehua Capital Management LLC (1.79Mn shares), Jane Street Group, LLC (1.72Mn shares), UBS Group AG (1.53Mn shares) and Morgan Stanley (1.34Mn shares), per Business Quant data.